Tocilizumab subcutaneous products — Medica

Initial criteria

• age > 18 years
• has tried one conventional synthetic DMARD for at least 3 months OR has already had a 3‑month trial with at least one biologic other than a tocilizumab product
• prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• therapy established for at least 6 months
• beneficial clinical response when assessed by at least one objective measure OR improvement in at least one symptom

Approval duration

initial: 6 months; reauth: 1 year